(Q39678200)

13 September 2017

title

Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL. (English)

1 reference

13 September 2017

1 reference

Sokoloff MH

1

1 reference

13 September 2017

Yang XJ

2

1 reference

13 September 2017

Fumo M

3

1 reference

13 September 2017

Mhoon D

4

1 reference

13 September 2017

Brendler CB

5

1 reference

13 September 2017

publication date

1 March 2004

1 reference

13 September 2017

1 reference

13 September 2017

volume

93

1 reference

13 September 2017

issue

4

1 reference

13 September 2017

page(s)

499-502

1 reference

Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Prostate cancer detection at low prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Verification bias and the prostate-specific antigen test--is there a case for a lower threshold for biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Prostatic foamy gland carcinoma with aggressive behavior: clinicopathologic, immunohistochemical, and ultrastructural analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

The definition and preoperative prediction of clinically insignificant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04657.X

10.1111/J.1464-410X.2003.04657.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference